# Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

> **NCT06086340** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 779 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Aromatase Inhibitor

## Key facts

- **NCT ID:** NCT06086340
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-29
- **Primary completion:** 2024-01-24
- **Final completion:** 2024-01-24
- **Target enrollment:** 779 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06086340

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06086340, "Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06086340. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*